CDC Reportedly Delays COVID Vaccine Study; FDA Rejects Melanoma Drug Again
Acting CDC Director Jay Bhattacharya is reportedly blocking publication of internal findings on COVID-19 vaccine effectiveness, according to The Washington Post citing two scientists with knowledge of the matter. Separately, the FDA has rejected Replimune's engineered-virus melanoma treatment for a second time, continuing a regulatory dispute over the experimental therapy. These developments occur alongside broader health news including Caribbean AMR laboratory initiatives, a $50 million Canadian hospital donation, and advances in portable diagnostic technology.
Progressive outlets frame the CDC's reported suppression of vaccine effectiveness data as a politically motivated interference in public health science, raising concerns about the integrity of federal health agencies under current leadership.
The Washington Post, citing two unnamed scientists, reports that Acting CDC Director Bhattacharya has delayed release of an internal study on COVID-19 vaccine effectiveness; the CDC has not publicly confirmed or denied the characterization of those actions.
Conservative outlets may argue that agency leadership has legitimate authority to review and verify scientific findings before publication, and that scrutiny of vaccine research reflects appropriate scientific rigor rather than censorship.
The Washington Post, citing two unnamed scientists, reports that Acting CDC Director Bhattacharya has delayed release of an internal study on COVID-19 vaccine effectiveness; the CDC has not publicly confirmed or denied the characterization of those actions.
Acting CDC Director Jay Bhattacharya has reportedly delayed publication of an agency study on COVID-19 vaccine effectiveness against emergency room visits and hospitalizations, according to The Washington Post.